[go: up one dir, main page]

GT201000102A - Producto de dispersión sólida de drogas basadas en n-aril urea - Google Patents

Producto de dispersión sólida de drogas basadas en n-aril urea

Info

Publication number
GT201000102A
GT201000102A GT201000102A GT201000102A GT201000102A GT 201000102 A GT201000102 A GT 201000102A GT 201000102 A GT201000102 A GT 201000102A GT 201000102 A GT201000102 A GT 201000102A GT 201000102 A GT201000102 A GT 201000102A
Authority
GT
Guatemala
Prior art keywords
aril
solid dispersion
urea
dispersion product
based drugs
Prior art date
Application number
GT201000102A
Other languages
English (en)
Spanish (es)
Inventor
Rudolf Schroeder
Tanja Heitermann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT201000102A publication Critical patent/GT201000102A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GT201000102A 2007-10-19 2010-04-16 Producto de dispersión sólida de drogas basadas en n-aril urea GT201000102A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99961807P 2007-10-19 2007-10-19

Publications (1)

Publication Number Publication Date
GT201000102A true GT201000102A (es) 2012-03-12

Family

ID=40089463

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201000102A GT201000102A (es) 2007-10-19 2010-04-16 Producto de dispersión sólida de drogas basadas en n-aril urea

Country Status (18)

Country Link
EP (1) EP2197425A2 (fr)
JP (1) JP2011500649A (fr)
KR (1) KR20100087170A (fr)
CN (1) CN101827584A (fr)
AU (1) AU2008313622A1 (fr)
BR (1) BRPI0818340A2 (fr)
CA (1) CA2699301A1 (fr)
CO (1) CO6270206A2 (fr)
CR (1) CR11442A (fr)
DO (1) DOP2010000117A (fr)
EC (1) ECSP10010183A (fr)
GT (1) GT201000102A (fr)
MX (1) MX2010004291A (fr)
PA (1) PA8800101A1 (fr)
RU (1) RU2010119929A (fr)
UA (1) UA100865C2 (fr)
WO (1) WO2009050291A2 (fr)
ZA (1) ZA201002095B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100176A2 (fr) * 2008-02-07 2009-08-13 Abbott Laboratories Forme pharmaceutique pour administration orale d’un inhibiteur de tyrosine kinase
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
MX2012014387A (es) * 2010-06-09 2013-05-01 Abbvie Inc Dispersiones solidas que contienen inhibidores de cinasa.
CA2855243C (fr) 2011-11-11 2020-04-14 Novartis Ag Procede de traitement d'une maladie proliferative
PE20141994A1 (es) 2011-11-23 2014-12-24 Novartis Ag Formulaciones farmaceuticas
WO2014003678A1 (fr) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Compositions pharmaceutiques comprenant de l'ambrisentan et des particules de dispersion solide contenant du tadalafil
WO2014003677A1 (fr) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Compositions pharmaceutiques comprenant des particules de dispersion solide contenant du tadalafil
US12133911B2 (en) 2015-06-09 2024-11-05 Capsugel Belgium Nv Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1959926A1 (fr) * 2005-10-25 2008-08-27 Abbott Laboratories Preparation comprenant un medicament faiblement soluble dans l'eau et son procede d'utilisation
WO2007066189A2 (fr) * 2005-12-09 2007-06-14 Pfizer Products Inc. Sels, promedicaments et formulations de 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-uree
JP2010509289A (ja) * 2006-11-09 2010-03-25 アボット ゲーエムベーハー ウント コンパニー カーゲー チロシンキナーゼ阻害剤の経口投与用薬学的剤形

Also Published As

Publication number Publication date
MX2010004291A (es) 2010-08-02
JP2011500649A (ja) 2011-01-06
CN101827584A (zh) 2010-09-08
DOP2010000117A (es) 2010-05-15
CA2699301A1 (fr) 2009-04-23
EP2197425A2 (fr) 2010-06-23
PA8800101A1 (es) 2009-05-15
CO6270206A2 (es) 2011-04-20
AU2008313622A1 (en) 2009-04-23
WO2009050291A3 (fr) 2010-04-08
RU2010119929A (ru) 2011-11-27
CR11442A (es) 2010-09-06
WO2009050291A2 (fr) 2009-04-23
UA100865C2 (ru) 2013-02-11
KR20100087170A (ko) 2010-08-03
ECSP10010183A (es) 2010-06-29
BRPI0818340A2 (pt) 2015-04-22
ZA201002095B (en) 2011-11-30

Similar Documents

Publication Publication Date Title
GT201000102A (es) Producto de dispersión sólida de drogas basadas en n-aril urea
GT201000095A (es) Producto de dispersión sólida que contiene un compuesto a base de n-aril urea
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
CL2015000942A1 (es) Compuestos de benceno sustituido.
CL2008000691A1 (es) Compuestos derivados de dihidro y tetrahidro oxazolopirimidinonas sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la esquizofrenia, epilepsia, entre otras enfermedades.
BR112014000178A2 (pt) composições tópicas
EP2917180A4 (fr) Agoniste du récepteur gpr40, procédés de préparation de celui-ci, et compositions pharmaceutiques contenant celui-ci en tant que substance active
UY31673A1 (es) "derivados heterocíclicos de urea y métodos de uso de los mismos-211"
CR20110599A (es) Composiciones farmacéuticamente activas que comprenden moduladores de estrés oxidativo (osm), nuevas entidades químicas, composiciones y usos
CL2011001497A1 (es) Compuestos derivados de heterociclos, modulador de gpr120; composicion farmaceutica; y su uso para el tratamiento de diabetes tipo i,ii y sindrome metabolico.
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
BR112014027039A2 (pt) formulação farmacêutica tópica não aquosa; uso de formulação farmacêutica não aquosa; formulação não aquosa; e método
CL2013000675A1 (es) Compuestos derivados de pirazolamida sustituidas, con actividad sobre pge2/ep4; composicion farmaceutica que los comprende; y su uso para el tratamiento de la esclerosis multiple y la artritis reumtoide.
WO2014059444A3 (fr) Moteurs chimiques et procédés pour leur utilisation, en particulier dans l'injection de fluides hautement visqueux
CL2007002971A1 (es) Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras.
BRPI0908097A2 (pt) uso de pelo menos um composto, peptídeo, e, formulação farmacêutica.
CL2011000064A1 (es) Proceso para preparar microparticulas de tamaño 10-500um que comprende contactar una mezcla de material biologicamente activo, un polimero y un auxiliar de procesamiento especifico con un fluido supercritico bajo temperatura y presion para que penetre y licuen al polimero y liberar presion para precipitar las microparticulas.
BR112015023434A8 (pt) compostos inibidores de histona deacetilase, seu uso e composição farmacêutica que os compreende
ECSP11010762A (es) Composición tópica para el tratamiento de queratosis actínica
CL2007003557A1 (es) Compuestos derivados de heterociclos de nitrogeno, inhibidores de la actividad sobre b-raf; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CL2009001215A1 (es) Composiciones farmaceuticas que comprenden un primer agente seleccionado del grupo consistente de i) un agente antiinflamatorio, ii) acetaminofeno, iii) fenacetina, iv) tramadol, y un segundo agente; uso de dichas composiciones para tratar enfermedades proliferativas incluyendo cancer.
CL2014003429A1 (es) Compuestos especificos derivados de indanosulfamida; composicion farmaceutica que los comprende, utiles en el tratamiento e la epilepsia.
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
GB201105050D0 (en) Pharmaceutical agent
CO2018001918A2 (es) Moléculas basadas en urea como plaguicidas, e intermediarios, composiciones y procesos, relacionados con ellas